Quick Order Cart

Cat. No. ARG43845

EXOC6 Knockout Hep-G2 Cell Line

  • Product Type:

    In Stock Cell Lines

  • Species:

    Homo sapiens (Human)

  • Tissue Source:

    Liver

  • Disease:

    Hepatoblastoma

The EXOC6 Knockout Hep-G2 Cell Line is a CRISPR/Cas9-edited loss-of-function model in a human hepatocellular carcinoma background, enabling the study of exocyst complex-mediated vesicle tethering and polarized secretion. This knockout cell line targets EXOC6, a subunit of the exocyst complex that functions downstream of RalA and Rab11 to regulate SNARE-mediated membrane fusion. Ideal for investigating cell polarity, cancer cell invasion, and secretory pathway regulation, this model supports assays such as Western blotting, immunofluorescence, secretion analysis, and migration/invasion assays. The Hep-G2 host provides a relevant liver epithelial context for metabolic and toxicology research, facilitating drug discovery for secretion-related disorders.

Inquire Now

In stock

Ships next business day


Ask a Question

Shipping Info:

Cryopreserved in vials and shipped on dry ice


Disclaimer:

For Research Use Only

  • Characteristics

    Host Cell

    Hep-G2

    Sex of Donor

    Male

    Age

    15 years

    Derived From Site

    In situ; Liver

    Gene Name

    EXOC6

    Gene Identifier

    NCBI Gene ID 54536

    Morphology

    Epithelial-like

    Growth Mode

    Adherent

    Storage

    Liquid nitrogen (LN2)

  • Culture Conditions

    Temperature

    37°C

    Atmosphere

    5% CO₂

  • Quality Control

    Sterility testing

    The bacterial, yeast, and fungi are not detected in these cells by daily monitor.

    Mycoplasma testing

    Negative for mycoplasma through PCR analysis

  • Disclaimer

    Intended Use

    This product is intended for laboratory in vitro use only. lt is not intended for diagnostic, therapeutic, or clinical applications.

    Disclaimer

    Ascent Research endeavors to provide accurate and up-to-date product information. However, no warranties or representations are made regarding its completeness or reliability. References to scientific literature and patents are for informational purposes only, and the customer assumes sole responsibility for verifying their accuracy.

    By accepting this product, the customer acknowledges and agrees to assume all risks associated with its receipt, handling, storage, disposal, and use, including compliance with all applicable safety and environmental regulations and precautions. Relevant laws, regulations, and ethical guidelines must be followed in conducting any research, modifications, or derivatives derived from this product.

    This product is provided "AS IS", and except as expressly stated herein, Ascent Research disclaims all other warranties, express or implied. Under no circumstances shall Ascent Research, its affiliates, or representatives be liable for indirect, incidental, consequential, or punitive damages arising from the use of this material. While Ascent Research employs rigorous quality control measures, we shall not be held responsible for damages resulting from misidentification or misinterpretation of the provided materials.

Description

The EXOC6 Knockout Hep-G2 Cell Line is a CRISPR/Cas9-edited human liver cancer cell line in which the EXOC6 gene has been disrupted to create a loss-of-function model. This cell line is derived from the Hep-G2 host cell background and is provided as a ready-to-use knockout cell line for advanced research applications. The targeted disruption of EXOC6 allows for the investigation of exocyst complex function and its role in polarized secretion and cell polarity.

The Hep-G2 cell line was originally isolated from a hepatocellular carcinoma of a 15-year-old Caucasian male and serves as a well-characterized epithelial model for metabolic and toxicology studies. Hep-G2 cells retain many liver-specific functions, including the secretion of plasma proteins and metabolic enzymes, making them a relevant system for studying hepatic exocytosis pathways. The epithelial nature and cancerous origin of these cells also render them suitable for investigations into tumor cell migration and invasion.

EXOC6 encodes a subunit of the evolutionarily conserved exocyst complex, which mediates the tethering of post-Golgi secretory vesicles to the plasma membrane, a critical step for exocytosis and cell polarity establishment. EXOC6 functions downstream of Ral GTPases, Rab11, and PIP2, and interacts with exocyst subunits (EXOC1-EXOC8), RalA, Rab proteins, and the Arp2/3 complex. The exocyst complex, including EXOC6, Sec3, Sec8, and Exo70, facilitates SNARE-mediated membrane fusion, enabling directional secretion of cargos like insulin. Disruption of EXOC6 impairs vesicle docking and fusion, leading to defective polarized secretion and loss of cell polarity, affecting neurite outgrowth and cell migration.

In the Hep-G2 hepatocellular carcinoma background, knockout of EXOC6 provides a powerful tool to dissect the role of the exocyst complex in liver cell biology and cancer progression. Given that Hep-G2 cells are capable of secreting hepatocyte-specific proteins and responding to metabolic cues, this knockout line enables the study of how exocyst-mediated trafficking contributes to hepatic secretory function. Moreover, because cell polarity and directed migration are crucial for cancer metastasis, the EXOC6 knockout Hep-G2 model is particularly suited for examining the molecular mechanisms underlying tumor cell invasion. The connection between EXOC6 and insulin secretion also offers a platform to investigate links between exocyst function and metabolic dysregulation, even in a non-pancreatic cell context.

This knockout cell line facilitates a wide range of experimental applications, including the analysis of exocytosis mechanisms via secretion assays and immunofluorescence-based visualization of vesicle trafficking. Researchers can employ Western blotting and co-immunoprecipitation to assess exocyst complex assembly and protein-protein interactions. Cell migration and invasion assays using this line can reveal the impact of EXOC6 loss on cancer cell motility, while drug discovery efforts targeting secretion-related disorders can utilize the line for phenotypic screening. For further technical information, scientific support, or to discuss custom requirements, please contact Ascent Research.

Reset Password

    Reach Us Questions? Click Me Here!

    Fill out the form below and a member of our team will contact you shortly!

    *Required field



      Reach Us

      Fill out the form below and a member of our team will contact you shortly!

      *Required field

      Product Inquiry (Optional)